Clinical Trial

CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers

Name: CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers — clinical trial record (NCT06358053)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

A single center, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cells in HLA-A\*02:01+ Subjects HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine RP2D of CRTE7A2-01 TCR-T cell injection.

Trial Details

NCT Number	NCT06358053
Lead Sponsor	Corregene Biotechnology Co., Ltd
Conditions	Cervical Cancer, Anal Cancer, Head and Neck Cancers, Other Solid Tumors
Enrollment	24 participants
Start Date	2024-04-15
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-04-30 (estimated)
Updated on ClinicalTrials.gov	2024-04-10